165 related articles for article (PubMed ID: 35233509)
1. Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia.
Hohtari H; Kankainen M; Adnan-Awad S; Yadav B; Potdar S; Ianevski A; Dufva O; Heckman C; Sexl V; Kytölä S; Mustjoki S; Porkka K
Hemasphere; 2022 Mar; 6(3):e701. PubMed ID: 35233509
[TBL] [Abstract][Full Text] [Related]
2. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
Johansson KB; Zimmerman MS; Dmytrenko IV; Gao F; Link DC
Leukemia; 2023 Dec; 37(12):2356-2366. PubMed ID: 37838759
[TBL] [Abstract][Full Text] [Related]
3. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
4. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
Van Goethem A; Yigit N; Moreno-Smith M; Vasudevan SA; Barbieri E; Speleman F; Shohet J; Vandesompele J; Van Maerken T
Oncotarget; 2017 Aug; 8(34):57047-57057. PubMed ID: 28915653
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
7. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
9. BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.
Tessoulin B; Papin A; Gomez-Bougie P; Bellanger C; Amiot M; Pellat-Deceunynck C; Chiron D
Front Oncol; 2018; 8():645. PubMed ID: 30666297
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia.
Zhang H; Gu L; Liu T; Chiang KY; Zhou M
PLoS One; 2014; 9(6):e100960. PubMed ID: 24968304
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
14. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
16. Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia.
Richter A; Lange S; Holz C; Brock L; Freitag T; Sekora A; Knuebel G; Krohn S; Schwarz R; Hinz B; Murua Escobar H; Junghanss C
Cell Death Discov; 2022 Jul; 8(1):302. PubMed ID: 35778418
[TBL] [Abstract][Full Text] [Related]
17. The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.
Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857559
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Guo Y; Wang FF; Xiang B; Ma HB; Gong YP
Oncol Lett; 2022 Jan; 23(1):7. PubMed ID: 34820006
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
20. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]